Evidence map›Paper›PMID 41782314›Full record

Observational studyAnnals of medicine2026

Advanced Parkinson's disease treatment patterns in Italy: results from a multicenter observational study.

Fabrizio Stocchi, Paolo Barone, Roberto Ceravolo, Maria Francesca De Pandis, Leonardo Lopiano, Nicola Modugno, Alessandro Padovani, Manuela Pilleri, Alessandro Tessitore, Mario Zappia

Abstract readObservational StudyMulticenter Study
In one paragraph

Observational study in Annals of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Fabrizio StocchiDepartment of Neurology, University San Raffaele Roma and IRCCS San Raffaele, Rome, Italy.ORCID 0000-0002-5763-0033
Paolo BaroneDepartment of Medicine, Surgery and Dentistry "Scuola Medica Salernitana," Neuroscience Section, University of Salerno, Baronissi, Italy.
Roberto CeravoloNeurodegenerative Disease Center, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Maria Francesca De PandisDepartment of Human Sciences and Promotion of Quality of Life, San Raffaele University, Roma, Italy.
Leonardo LopianoDepartment of Neuroscience Rita Levi-Montalcini, University of Turin; AOU Città della Salute e della Scienza, Turin, Italy.
Nicola ModugnoI.R.C.C.S. Neuromed, Pozzilli, Isernia, Italy.
Alessandro PadovaniNeurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
Manuela PilleriUO Neurologia Casa di Cura Villa Margherita, Arcugnano Vicenza, Italy and Centro Parkinson e Parkinsonismi ASST Gaetano Pini CTO, Milano, Italy.
Alessandro TessitoreDepartment of Advanced Medical and Surgical Sciences, University of Campania "L. Vanvitelli", Naples, Italy.
Mario ZappiaDepartment "G.F. Ingrassia", University of Catania, Catania, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesSubstitution therapy with oral levodopa is the primary treatment of Parkinson's disease (PD). However, long-term levodopa use is associated with fluctuations in response and dyskinesia. These complications severely affect the patient quality of life. Fluctuation management in long-standing PD is poorly documented. The Parkinson's Disease Fluctuations treatment Pathway (PD-FPA) study was an Italian multicenter, observational study designed to describe how fluctuations are treated in patients with advanced disease. PATIENTS AND

methodsBetween July 2018 and December 2020, ten centres enrolled consecutive patients aged ≥18 years who had been diagnosed with PD 10-15 years before enrollment and had been experiencing fluctuations for at least 2 years before enrollment. Data on patient characteristics, PD stage, fluctuations, and treatments were collected at enrollment (T0) and prospectively at 6 months (T1) and 12 months (T2). Data were also collected retrospectively, at 1 and 2 years before T0.

resultsAt T0, patients (

conclusionMaintenance of stable disease in patients with long-standing PD and fluctuations is feasible with non-invasive treatments. Accurate treatment adjustments and individualized strategies with new-generation add-on drugs may be of key importance.

Indexed as

Antiparkinson AgentsLevodopaParkinson DiseaseAgedAlanineBenzylaminesCatechol O-Methyltransferase InhibitorsDrug SubstitutionDyskinesiasFemaleHumansItalyMaleMiddle AgedMonoamine Oxidase InhibitorsOxadiazolesAlanineAntiparkinson AgentsBenzylaminesCatechol O-Methyltransferase InhibitorsLevodopaMonoamine Oxidase InhibitorsopicaponeOxadiazolessafinamideCOMT inhibitordyskinesiafluctuationlevodopaMAOB inhibitoropicaponeParkinson diseasesafinamidewearing-off

Identifiers

PMID41782314
PMCPMC12964474

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.